To understand the essence of evidence got from a number of phase 2 trials and also the donations of phase 3 trials of medication, vaccines and medical devices, FDA studied 2-2 recent cases by which promising phase 2 clinical trial results weren’t confirmed in period 3 clinical testing. Period 3 studies didn’t confirm phase-2 findings of efficacy at 14 cases, safety in 1 instance, and both security and efficacy in seven cases. These unexpected results may occur even once the phase two analysis was relatively big as well as though the phase 2 trials evaluated clinical outcomes.
These case studies reveal that high phase 3 randomized controlled trials may create significant evidence across all kinds of merchandise, patients, as well as even diseases. Both security and efficiency failures happened even if the phase 2 studies had been relatively high, and also though the merchandise was approved for one more condition. Sometimes, the phase 3 analysis demonstrated that shortterm consequences found at the phase two study weren’t related to a longterm benefit or that the merchandise needed toxicity which wasn’t found at the phase two study.
Our most popular topics on Managedcaremag.com
Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.